0001437749-22-002398.txt : 20220203
0001437749-22-002398.hdr.sgml : 20220203
20220203171444
ACCESSION NUMBER: 0001437749-22-002398
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220201
FILED AS OF DATE: 20220203
DATE AS OF CHANGE: 20220203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pascoe Richard W
CENTRAL INDEX KEY: 0001343266
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36913
FILM NUMBER: 22589655
MAIL ADDRESS:
STREET 1: C/O SEELOS THERAPEUTICS, INC.
STREET 2: 300 PARK AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KEMPHARM, INC
CENTRAL INDEX KEY: 0001434647
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205894398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
BUSINESS PHONE: (321) 939-3416
MAIL ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM INC
DATE OF NAME CHANGE: 20080507
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-02-01
0001434647
KEMPHARM, INC
KMPH
0001343266
Pascoe Richard W
C/O KEMPHARM, INC.
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION
FL
34747
1
1
Executive Chairman
Stock Option (right to buy)
7.17
2022-02-01
4
A
0
127286
0
A
2032-01-31
Common Stock
127286
127286
D
Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Richard W. Pascoe
2022-02-03